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Abstract
This retrospective study examines the outcomes of sclerotherapy in children with (veno)lymphatic malformations who received
sclerotherapy between 2011 and 2016 (116 children, 234 procedures). Complication severity was classified using the Society of
Interventional Radiology classification. Clinical response was rated on a scale of 0 (no change) to 3 (good improvement). The
sclerosants used were bleomycin (n = 132; 56%), lauromacrogol (n = 42; 18%), doxycycline (n = 15; 6%), ethanol (n = 12; 5%),
or a combination (n = 33; 14%). Four major and 25 minor complications occurred without significant differences between the
agents. The median response rate per procedure was 2—some improvement—for all sclerosants. However, in pure LMs (67%),
bleomycin and a combination of agents resulted in the best clinical response. On patient level, all had some or good clinical
response. Mixed macrocystic and microcystic lesions showed a significantly lower clinical response (median 2 versus 3; p =
0.023 and p = 0.036, respectively) and required significantly more procedures (median 2 versus 1; p = 0.043 and p = 0.044,
respectively) compared with lesions with one component.
Conclusion: Sclerotherapy for (V)LMs in children is safe and effective. Bleomycin is the most frequently used agent in this
clinic and seemed most effective for pure LMs. Mixed macrocystic and microcystic lesions are most difficult to treat effectively.
What is Known:
• A variety of agents can be used for sclerotherapy of lymphatic malformations in children.
• Macrocystic lesions have favorable outcomes compared with microcystic and mixed lesions.
What is New:
• Bleomycin and a combination of agents seem to be most effective to treat lymphatic malformations in children.
• Mixed macrocystic and microcystic lesions are more difficult to treat effectively compared with lesions with either one of these components.
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Lymphatic malformations (LMs) are congenital developmen-
tal anomalies of the lymphatic system, with or without a ve-
nous component (venolymphatic malformation; VLM) [1].
The incidence is estimated to be 1 in 2000–6000 live births
[2–5]. Symptoms, often named lesion-related complications,
vary from pain and swelling to relapsing periods of infection
and distortion of anatomical structures. Sclerotherapy is cur-
rently the gold standard for (V)LM treatment if invasive man-
agement is indicated [6], and a wide range of sclerosing agents
have been used in daily practice, including bleomycin,
lauromacrogol, doxycycline, ethanol, and picibanil.
Several studies evaluated treatment outcomes after use of
various agents for sclerotherapy in (V)LMs [7–17]. However,
most of these studies included small patient cohorts [9, 16, 17]
or both adults and children [8, 11, 12, 15], which could con-
found or bias the results. Among these studies, those examin-
ing larger pediatric cohorts lack information on bleomycin
[10, 13, 14], which is currently one of the most frequently
used agents worldwide. In a systematic review on agents used
for sclerotherapy, it is concluded that the optimal sclerothera-
py could not be identified and that the difference in complica-
tion rates could be the deciding factor in the choice between
agents [18].
Therefore, this study evaluates sclerotherapy outcomes of
(V)LMs in children treated in a high volume center where
different sclerosing agents are being used. These data will
provide more insight into the optimal agent for sclerotherapy
of (V)LMs and will provide guidance in the counseling of
children and their parents on the treatment and prognosis.
Methods
Data collection
A retrospective analysis was performed of all children (< 18
years of age) with (V)LMs who received percutaneous sclero-
therapy between January 2011 and December 2016. Minimal
follow-up was 6 months. All patients were treated at the ex-
pertise center for hemangiomas and congenital vascular
malformations (HECOVAN) at the Radboudumc-Amalia
Children’s Hospital in Nijmegen, Netherlands. The local eth-
ical committee approved this study.
Medical records were reviewed for patient age at diagnosis
and procedure, sex, comorbidity, the number of sclerotherapy
procedures during the study period, and the lesion-related
complications prior to sclerotherapy. Lesion characteristics
included anatomical location and morphological subtype. As
regards the anatomical location, six regions were defined: (1)
head/neck area, (2) thorax, (3) abdomen/pelvis, (4) upper ex-
tremity, (5) lower extremity, and (6) abdomen/pelvis and low-
er extremity. Morphologically, the lesions were classified as
macrocystic, microcystic, or mixed macro- and microcystic
and, secondly, as pure lymphatic (LM) or venolymphatic
(VLM). The difference between macrocystic and microcystic
was defined by the size and accessibility of the cysts [1, 6, 8,
19]. Macrocystic lesions contain cysts ≥ 2 cm or considered
accessible for aspiration based on ultrasound. Microcystic le-
sions contain cysts < 2 cm or considered inaccessible for as-
piration. Mixed lesions contain both macrocystic and
microcystic components. VLMs have both venous and lym-
phatic components.
Outcome parameters
The outcome parameters were short-term (< 30 days)
and long-term procedure-related complications and clin-
ical response rate. Post-treatment pain, local swelling,
and transient fever without focus of infection were not
considered complications, but expected side effects of
sclerotherapy. The procedure-related complications were
classified as minor or major according to the Society of
Interventional Radiology (SIR) Classification System for
Complications by Outcome (Table 1) [20]. Nominal therapy
included oral antibiotic treatment. Complications requiring







A: No therapy; no consequence
B: Nominal therapy; no consequence
(includes overnight admission for
observation only)
Major complications
C: Require treatment; minor
hospitalization (< 48 h)
D: Require major therapy, unplanned
increase in level of care, prolonged
hospitalization (> 48 h)
E: Permanent adverse sequelae
F: Death
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The clinical response was based on documentation in the
patient records, similar to other studies [8, 10], and expressed
on a scale of zero to three. Zero represents no response to
treatment. One represents slight improvement, defined as little
regression compared with the original size with almost no
cosmetic relief or functional improvement. Two represents
some improvement, defined as visible regression of the lesion
compared with the original size with some cosmetic relief or
functional improvement. Three represents a good response,
defined as total or near-total volume reduction of the lesion
with no or minimal residual cosmetic or functional
impairment.
Technique of sclerotherapy
Sclerotherapy is performed under general anesthesia.
Sclerotherapy of lymphatic malformations in children can be
challenging due to the small size of the cysts or lymph vessels
and the limited safety margins of the agents used. In addition,
some of the agents could generate an intense pain response.
General anesthesia generates a controlled environment, facil-
itating targeted sclerotherapy: limiting the number of injec-
tions and radiation hazard needed and injecting the sclerosing
agent as specific as possible. In our opinion, sclerotherapy
under general anesthesia also minimizes psychic trauma.
This is an important part to take into account, in particular
because a treatment course of sclerotherapy could include
multiple sessions.
After puncturing the lesion with a 21–23 gauge needle
using ultrasound guidance, as much fluid as possible is aspi-
rated. Either bleomycin (Bleomedac, Lamepro BV, Breda,
Netherlands; 600 IU/kg, age < 1 year: max 10.000 IU, age >
1 year: max 15.000 IU per session), lauromacrogol
(Aethoxysklerol, Chemical Factory Kreussler & Co.,
Wiesbaden, Germany; either as a liquid with a concentration
of 2% or as foam; 2 ml lauromacrogol 2% with 8 ml sterile
room air, max 20–30 ml foam), doxycycline (Vibramycin,
Pfizer, Capelle aan den IJssel, Netherlands; 10 mg/ml, max
20 mg/kg), or ethanol (Alcohol, Pharmacy A15, Gorinchem,
Netherlands; max 0.14 ml/kg/10 minutes and max 0.5–1.0 ml/
kg per session) is injected under ultrasound guidance. Ethanol
sclerotherapy for macrocystic lesions involves both injection
and subsequent aspiration of the agent (rinsing). Additional
fluoroscopy guidance is used in case of macrocystic lesions or
a (suspected) venous component to visualize drainage into
normal soft tissue or circulation.
Choice of used agent
Bleomycin is the preferred sclerosant for LMs in our center
and also one of the most frequently used agents worldwide
[18]. The choice for another agent or a combination of agents
was based on location, content, extent, morphological type of
the (V)LM, and volume of bleomycin that could be used
based on weight of the patient and the cumulative lifetime
dose. At locations where only minimal swelling was allowed,
such as the eyelid or in close proximity to a nerve, bleomycin
was highly preferred over one of the other agents. In other
cases, when swelling was allowed, for example, in case of
an intra-abdominally located lesion, ethanol or lauromacrogol
was used. Another aspect was the morphological subtype of
the lesion. Microcystic lesions were preferably treated with
bleomycin or doxycycline. The agent of choice for
macrocystic lesions depended on the location as described
previously. Venolymphatic malformations were often treated
with ethanol or lauromacrogol in addition to bleomycin, be-
cause of the venous component. Ethanol was used preferen-
tially in more severe or extensive lesions, and a combination
of agents was often used in case of large lesions.
Statistical analyses
Complications and response rates were compared on pa-
tient and procedure level between the different scleros-
ing agents, the regions of anatomical location, and the
morphological subtypes. The statistical analyses were
performed with IBM SPSS statistical software version
25. Categorical data were presented as frequencies and
percentages and analyzed using Pearson’s chi-square or
Fisher’s exact test where appropriate. For continuous
data, means and standard deviations or medians and
ranges were calculated depending on the distribution of
data. For the results of clinical response (ordinal data),
both means and medians were calculated. Analyses were
performed using the independent t test or the ANOVA
in case of normal distribution and the Mann-Whitney U
test or Kruskal-Wallis test in case of non-normal distri-
bution. A p value of < 0.05 was considered significant.
Results
Patient demographics and lesion characteristics
A total of 234 sclerotherapy procedures were performed
in 116 children (53 males, 63 females) during the study
period. Table 2 summarizes the lesion characteristics of
this study population. A pure LM was diagnosed in 78
patients (67%) and a VLM in 38 patients (33%). Age at
first sclerotherapy procedure ranged from 1 day to 9
years, with a median of 7 years. Four patients required
ex-utero intrapartum therapy (EXIT) with direct endotra-
cheal intubation because of a potentially airway-
threatening LM. Five patients had a (V)LM in the con-
text of lymphangiomatosis (n = 2) or Klippel-Trenaunay
syndrome (n = 2).
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Most patients suffered frommultiple lesion-related compli-
cations before the first procedure during the study period
(Table 2). Sixteen patients (14%) required treatment for their
lesion-related complications prior to the study period, includ-
ing antibiotics (n = 7), tracheal cannulation (n = 2), cyst drain-
age because of compression (n = 2), and amputation of the
lower leg (n = 1). One-third of the patients (n = 36) received
treatment for their malformations prior to the study period, of
whom nine (8%) had a surgical resection.
The median number of sclerotherapy procedures per pa-
tient during the study period was one (range 1–13). Of all
patients, 55% received one and 18% two procedures. The
sclerosing agents used were bleomycin (n = 132; 56%),
lauromacrogol (n = 42; 18%), doxycycline (n = 15; 6%), eth-
anol (n = 12; 5%), or a combination of agents (n = 33; 14%).
Combination therapy consisted of bleomycin and ethanol (n =
6), bleomycin and lauromacrogol (n = 19), or lauromacrogol
and ethanol (n = 8).
Procedure-related complications
A total of 25 minor and four major complications were iden-
tified in 24 patients. No known cases of pulmonary toxicity
were seen during the study period. Table 3 shows the
procedure-related complications in the total group and for
each sclerosing agent used. No significant differences were
found in the occurrence of complications between the agents
and between the different morphological subtypes. Post-
procedural pain was an expected outcome, although it was
specifically reported in twelve patients, of which seven treated
with bleomycin, two with doxycycline, and the remainder all
with different combinations of sclerosants.
A total of 22 short-term minor complications were identified.
Hematoma was the most common complication (n = 16). Two
patients were treated with oral antibiotics for an infection. One of
these patients had a tracheal cannula because of the LM and
developed pneumonia 7 days after sclerotherapywith bleomycin.
The four “other” complications were skin necrosis (n = 1;
bleomycin), febrile convulsion (n = 1; bleomycin), blistering (n
= 1; lauromacrogol), and stridor (n = 1; lauromacrogol).
Four patients developed a short-term major complication.
Two patients were diagnosed with an abscessed LM cyst, for
which antibiotic treatment and drainage of the cyst were indicat-
ed. Two patients suffered from severe post-procedural swelling
with functional impairment. One of these developed an abnormal
gait and the other a reduced vision to 15%. Both required a
resection of the swollen LM to reduce the functional impairment.
Three long-term procedure-related complications occurred
during the study period, all after treatment with bleomycin.
These were scarring, hyperpigmentation, and lymphedema.
The lymphedema was treated with compression therapy.
Clinical response rate
The clinical response to sclerotherapy with the various agents
per procedure is summarized in Table 4. A total of 214 pro-
cedures (91%) resulted in “some” (n = 160; 68%) or “good” (n
= 54; 23%) clinical improvement. A response of 2 (some) or 3
(good) was reported after 93% of the procedures in case of
bleomycin or lauromacrogol injection, 75% after ethanol,
73% after doxycycline, and 97% after injection of a combina-
tion of agents. Table 5 shows the post hoc analysis of the
differences in response rates shown in Table 4. For the total
group, bleomycin and a combination of agents were signifi-
cantly better than doxycycline (means 2.2 and 2.1 versus 1.7,
p = 0.010 and p = 0.030). In pure lymphatic lesions,
bleomycin (mean 2.2) and a combination of agents (mean
2.3) were significantly better than both doxycycline (mean
1.7; p = 0.021 and p = 0.014) and ethanol (mean 1.4; p =
0.023 and p = 0.020). Lauromacrogol resulted in a mean re-
sponse rate of 2.1; this was not significantly different com-
pared with the other agents.
Table 2 Lesion characteristics
Total group (n = 116)
Diagnosis of the lesion
In utero 15 (13%)
At birth 47 (41%)
< 1 year 12 (10%)
1–2 years 10 (9%)
> 2 years 30 (26%)
Type of malformation







Head and neck 57 (49%)
Thorax 20 (17%)
Abdomen and pelvis 14 (12%)
Upper extremity 8 (7%)
Lower extremity 10 (9%)
Abdomen/pelvis/lower extremity 7 (6%)
Lesion-related complications
Increase in size 70 (60%)
Pain 50 (43%)
Functional impairment 37 (32%)
Cosmetically disturbing lesion 34 (29%)
Infection 13 (11%)
Bleeding 11 (9%)
Oppression of other structures 10 (9%)
Airway permeability threatened 6 (5%)
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In the evaluation on patient level, at the end of the study
period, 65 patients (56%) had shown some clinical response after
a median of two procedures (range 1–13), and 51 patients (44%)
had shown good clinical response after a median of one proce-
dure (range 1–4). The clinical response per patient was signifi-
cantly influenced by the morphological subtype of the lesion (p =
0.042) and the location of the lesion (p = 0.043). The clinical
response was better in macrocystic (median 3, range 2–3) and
microcystic lesions (median 3, range 2–3) compared with mixed
lesions (median 2, range 2–3; p = 0.023 and p = 0.036, respec-
tively). The number of procedures performed per patient during
the study period was also significantly higher in patients with a
mixed lesion (median 2, range 1–13) comparedwith patientswith
a macrocystic (median 1, range 1–7; p = 0.043) or microcystic
lesion (median 1, range 1–5; p = 0.044). The median response in
patients with a lesion in the head and neck area was significantly
better (median 3) than in patients with a lesion in the abdomen
and pelvis (median 2; p = 0.028) or in the upper extremity (me-
dian 2; p = 0.028). At the end of the study period, seven patients
of this cohort received treatment with an mTOR inhibitor due to
an insufficient response to sclerotherapy on the long term.
Discussion
This study aimed to evaluate the treatment of (V)LMs in a
large pediatric cohort and found that bleomycin and a combi-
nation of agents were superior in the treatment of pure LMs.
Furthermore, the study indicates that lesions with both
macrocystic and microcystic components are more difficult
to treat than lesions with either one of these components.
This study shows that all sclerosing agents are effective
with some or good clinical improvement after 91% of the
procedures. On patient level, all patients had shown some or
good clinical response at the end of the study period. This is a
good outcome compared with the range described in the sys-
tematic review of Horbach et al. showing an overall response
rate ranging from 67 to 100% per patient [18].
The present study indicates that bleomycin and a combina-
tion of agents result in a better clinical response compared with
doxycycline and ethanol. However, caution must be applied
with the interpretation of our data, because doxycycline and
especially ethanol were used in specific cases in this cohort.
Doxycycline was used, for example, when bleomycin was














Short term 26 (11%) 15 (11%) 5 (12%) 2 (13%) – 4 (12%) 0.792
Minor
Hematoma 16 10 2 1 – 3 0.819
Other 4 2 2 - – – 0.493
Infection 2 1 - - – 1 0.653
Major
Infection/abscess 2 1 – 1 – – 0.150
Functional
impairment
2 1 1 – – – 0.793
Long term 3 (1%) 3 (2%) – – – – 0.672
Minor
Scarring 1 1 – – – – 0.942
Hyperpigmentation 1 1 – – – – 0.942
Lymphoedema 1 1 – – – – 0.942
Table 4 Response rate per procedure
Response rate (scale 0–3) Total Group Bleomycin Lauromacrogol Doxycycline Ethanol Combination p value
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relatively contraindicated or not available. Ethanol is the pre-
ferred agent, based on expert opinion, for more severe or ex-
tensive lesions or lesions with a venous component.
Unfortunately, these data only included a small number of
patients.
On patient level, the response rates were significantly
influenced by the morphological subtype: (V)LMs with
both macrocystic and microcystic components were found
to have lower response rates than lesions with either one
of these components. The median number of procedures
per patient was also higher in these mixed (V)LMs. It has
been described previously that better results were
achieved in macrocystic LMs compared with microcystic
and/or mixed lesions [7, 9, 21–25]. However, in contrast
to these studies, the present study shows that the results in
microcystic lesions were similar to those in macrocystic
lesions. Despite the good results for microcystic and
macrocystic lesions, it is unexplained why mixed lesions
responded inferiorly to sclerotherapy.
This study shows that sclerotherapy is a good first-line treat-
ment for (V)LMs in case invasive management is necessary.
However, the beneficial results of sclerotherapy do not always
persist on the long term or patients suffer from residual disease
[26], which was also the case in some patients in this cohort. The
mTOR inhibitor sirolimus has been found to be effective in
lymphatic malformations that were refractory to standard treat-
ment [27, 28]. Current clinical trials further investigate the use of
sirolimus and which patients would benefit most from this treat-
ment, with or without sclerotherapy or surgery.
Regarding the complication rates, no significant differ-
ences were found between the sclerosing agents nor the dif-
ferent morphological subtypes. Bleomycin is currently one of
the most frequently used sclerosing agents worldwide, and
complications rates in literature range from 0 to 20% [6, 12,
19, 29–34]. The most common complications reported are
infections, hematomas, and hyperpigmentation [6, 31, 32,
34, 35], which is in accordance with our results (Table 3).
A major concern in the use of bleomycin is the risk of
pulmonary toxicity, which is shown to be a rare and dose-
related risk [36]. In this study, being one of the largest cohorts
studied, no known cases of pulmonary toxicity were
identified. Thus, the risk of bleomycin-induced pulmonary
toxicity seems to be negligible when used in dosages docu-
mented in our protocol. The patient who developed a pneu-
monia after bleomycin injection had a bacterial pneumonia
and furthermore a high risk a priori because of a tracheal
cannula in situ. Currently, no standard follow-up protocol is
used in our hospital to quantify pulmonary function after use
of bleomycin. Whether the addition of pulmonary function
tests and/or radiographic assessment to current standard care
is useful and cost-effective in the detection of pulmonary com-
plications after use of bleomycin has not yet been clarified.
Regarding the other agents used in our center, complication
rates were similar to those reported in other studies [5, 21, 22,
37–42]. The complication rate of lauromacrogol ranged from
0 to 24% in literature, including infections (3%) and hemato-
mas (13–24%) [21, 37]. Our population had a complication
rate of 12% without infections and fewer cases of hematomas
(5%). Complication rates after doxycycline injection ranged
from 0 to 14% in literature, including infection and hemor-
rhage [5, 22, 38–40], which was similar in our study popula-
tion (13%). Ethanol was only used in a few exceptional cases,
and no complications were identified, which is in accordance
to known studies [41, 42].
This study has some limitations inherent to the retrospec-
tive study design, in which randomization of the agent was not
performed. Considerations on which agent to be used in spe-
cific cases were based on expert opinion, since no internation-
al guidelines are currently available. Unfortunately, the reason
of this choice was not always well documented. The size of
the study is a strength in comparison with other studies, but
still the reliability of statistical analyses is limited for smaller
subgroups. The response rate was determined based on clini-
cal descriptions in the patients’ records, which is subject to the
perception of the physician. This may influence the reliability
of data, but it probably does not compromise the ability to
assess for trends. Future studies are recommended to investi-
gate which approach is best to measure and quantify response
after sclerotherapy of (V)LMs, for example, patient-reported
outcomes, physical examination, or post-procedural imaging.
In these studies, it could be beneficial to use the updated SIR
classification, if this is validated properly for a widespread use
[43]. Patient-related outcomes are particularly important to
focus on in future studies, as proposed by the OVAMAproject
[44]. In this consensus study, a core outcome set was devel-
oped for clinical research on peripheral vascular
malformations, and international consensus was reached that
patient-reported outcomes play a significant role. These in-
clude the item pain and it would be interesting to investigate
the differences in intensity and duration of pain between var-
ious sclerosing agents. Overall, prospective studies are needed
to strengthen the results to determine the most potent scleros-
ing agent in each subtype and to develop guidelines for
patient- or lesion-specific care.
Table 5 Post hoc analysis of response rate per procedure
Total group Pure lymphatic
p value 0.071 0.021
Bleomycin vs doxycycline 0.010 0.021
Bleomycin vs ethanol 0.282 0.023
Combination vs doxycycline 0.030 0.014
Combination vs ethanol 0.488 0.020
Lauromacrogol vs doxycycline 0.061 0.641
Lauromacrogol vs ethanol 0.243 0.147
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Conclusions
Complication rates after sclerotherapy of (veno)lymphatic
malformations in children are low and mostly include minor
complications. No significant differences were found in com-
plication rates between the different sclerosing agents. All
agents are effective; however, bleomycin and a combination
of agents seem to be most effective in the treatment of pure
lymphatic malformations. In clinical care, special attention
should be paid to mixed macrocystic and microcystic
(veno)lymphatic malformations, because the results of this
study indicate that these lesions are more difficult to treat
effectively compared with lesions with either one of these
components.
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